Winship Executive Director Suresh S. Ramalingam, MD, was awarded the Paul A. Bunn, Jr. Scientific Award September 9 at the 2023 IASLC World Conference on Lung Cancer.
Suresh S. Ramalingam, MD, executive director of Winship Cancer Institute of Emory University, was awarded the Paul A. Bunn, Jr. Scientific Award September 9 at the 2023 IASLC World Conference on Lung Cancer.
Ramalingam also serves as professor and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine.
Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for patients with lung cancer harboring an EGFR mutation, resulting in FDA approval of third-generation inhibitors for metastatic non-small cell lung cancer.
He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 400 peer-reviewed publications, with over 36,000 citations and a H-index of 80. His research has been published in leading journals including the NEJM, Lancet, Science, Nature, PNAS, JCI, JCO, and JTO.
Additionally, Ramalingam serves as the principal investigator for the Emory University Lung Cancer SPORE award from the NCI. He serves as deputy chair for Therapeutics Programs at ECOG-ACRIN and is a former chair of the ECOG-ACRIN Thoracic Malignancies Committee and is currently the editor-in-chief of Cancer, a journal published by the American Cancer Society.
Ramalingam has received several awards throughout his career as a medical oncologist, researcher and health care leader, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI Clinical Investigators Team Leadership Award (2010-12). Ramalingam served as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) (2017-21) and as a member of the NCI Thoracic Malignancies Steering Committee (2012-2021). He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.
Presented by the International Association for the Study of Lung Cancer (IASLC), The Paul A. Bunn, Jr. Scientific Award recognizes an IASLC scientist for a lifetime achievement of scientific contributions to thoracic cancer research. Paul Bunn’s studies set worldwide standards for the treatment of lung cancer and identified issues of natural history and biomarkers of prognosis and therapy selection. Robert Ginsberg, MD, a thoracic surgeon from Toronto, Canada, earned the first award in 1994 for his contributions to the surgical treatment of early-stage lung cancer. Initially named the Scientific Award, the IASLC renamed the award in honor of Bunn after he served as the society’s executive director and CEO for 10 years.
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit https://www.iaslc.com for more information.
